Endo Pharmaceuticals:

From LBO to…?

BY GROUP 3
 Capability Enhancement
 Working with Endo will enhance Algos capability
in terms of working with FDA and getting the
approval for their new drug - MorphiDex.
 Endo's capability would be enhanced in terms
of research and clinical testing infrastructure
which would accelerate Endo to venture into
new product development.
 With the success of MorphiDex, Endo will be
able to expand into all pain management
categories.
 Merger with Endo and successful approval for
MorphiDex, will give Algos the capability to
expand their product lines with multiple dose
formulations.
 Both Algos and Endo will benefit from R&D
capability enhancements.